Japan Tissue Engineering Co (TSE:7774) Beneish M-Score: -2.88 (As of Jul. 09, 2026)


TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
60 GF Score
Price 円630.00
GF Value 円517.18
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co Beneish M-Score?

Japan Tissue Engineering Co TSE:7774 -0.32% 60 Beneish M-Score is -2.88 as of Jul. 09, 2026. GuruFocus rates TSE:7774 with a GF Score™ of 60/100 and a GF Value™ of 円517.18 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 822 Biotechnology companies, Japan Tissue Engineering Co ranks better than 71.05% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.88 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Japan Tissue Engineering Co's Beneish M-Score or its related term are showing as below:

TSE:7774' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -2.54   Max: -1.57
Current: -2.88

During the past 13 years, the highest Beneish M-Score of Japan Tissue Engineering Co was -1.57. The lowest was -3.39. And the median was -2.54.


Japan Tissue Engineering Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co Beneish M-Score Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.69 -1.57 -2.40 -2.03 -2.88

Japan Tissue Engineering Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.40 0.00 -2.03 0.00 -2.88

TSE:7774 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Japan Tissue Engineering Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Japan Tissue Engineering Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Japan Tissue Engineering Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Japan Tissue Engineering Co's Beneish M-Score falls into.


TSE:7774
60GF Score
Japan Tissue Engineering Co Ltd TSE:7774
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Japan Tissue Engineering Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Japan Tissue Engineering Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.061+0.528 * 1.06+0.404 * 0.7022+0.892 * 0.8889+0.115 * 0.953
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.3419+4.679 * -0.043416-0.327 * 1.0081
=-2.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円513 Mil.
Revenue was 円2,183 Mil.
Gross Profit was 円1,267 Mil.
Total Current Assets was 円4,182 Mil.
Total Assets was 円5,683 Mil.
Property, Plant and Equipment(Net PPE) was 円1,337 Mil.
Depreciation, Depletion and Amortization(DDA) was 円157 Mil.
Selling, General, & Admin. Expense(SGA) was 円88 Mil.
Total Current Liabilities was 円561 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.
Net Income was 円-735 Mil.
Gross Profit was 円0 Mil.
Cash Flow from Operations was 円-488 Mil.
Total Receivables was 円544 Mil.
Revenue was 円2,455 Mil.
Gross Profit was 円1,511 Mil.
Total Current Assets was 円4,825 Mil.
Total Assets was 円6,513 Mil.
Property, Plant and Equipment(Net PPE) was 円1,420 Mil.
Depreciation, Depletion and Amortization(DDA) was 円158 Mil.
Selling, General, & Admin. Expense(SGA) was 円74 Mil.
Total Current Liabilities was 円637 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(512.669 / 2182.744) / (543.572 / 2455.474)
=0.234874 / 0.221372
=1.061

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1511.234 / 2455.474) / (1267.353 / 2182.744)
=0.615455 / 0.580624
=1.06

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (4182.077 + 1336.84) / 5682.993) / (1 - (4824.949 + 1420.255) / 6512.99)
=0.028871 / 0.041116
=0.7022

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2182.744 / 2455.474
=0.8889

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(158.474 / (158.474 + 1420.255)) / (157.382 / (157.382 + 1336.84))
=0.100381 / 0.105327
=0.953

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(87.69 / 2182.744) / (73.511 / 2455.474)
=0.040174 / 0.029938
=1.3419

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 560.509) / 5682.993) / ((0 + 637.229) / 6512.99)
=0.098629 / 0.09784
=1.0081

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-734.751 - 0 - -488.02) / 5682.993
=-0.043416

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Japan Tissue Engineering Co has a M-score of -2.88 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.88 mean?
Japan Tissue Engineering Co (TSE:7774) has a Beneish M-Score of -2.88 as of Jul. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Japan Tissue Engineering Co and its competitors. According to the industry distribution chart, Japan Tissue Engineering Co ranks #238 out of 822 companies in the Biotechnology industry, placing it in the top 29%.
Is Japan Tissue Engineering Co's Beneish M-Score too high?
Japan Tissue Engineering Co's current Beneish M-Score is -2.88. Based on the distribution chart, Japan Tissue Engineering Co ranks #238 out of 822 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Japan Tissue Engineering Co has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Japan Tissue Engineering Co ranks #238 out of 822 companies for Beneish M-Score. This puts Japan Tissue Engineering Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Beneish M-Score is -2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Modestly Overvalued. The stock's GF Value™ is 円517.18, compared to a current price of 円630.00 — trading 21.8% above its estimated fair value. The current Beneish M-Score is -2.88. Japan Tissue Engineering Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Beneish M-Score is -2.88 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円630.00 is trading 21.8% above its estimated GF Value™ of 円517.18. GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.

Key valuation signals for TSE:7774:

  • Beneish M-Score: -2.88
  • GF Value™: 円517.18 vs. price of 円630.00 (21.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
60GF Score

Get the complete analysis for TSE:7774

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円630.00
Price
円517.18
GF Value